key: cord-0909092-t807er8k
authors: Pierce, Jacob; Stevens, Michael P.
title: COVID-19 and Antimicrobial Stewardship: Lessons Learned, Best Practices and Future Implications
date: 2021-10-05
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.10.001
sha: bf74ccfe8d7195b4a179ad69f61cec09bc743a92
doc_id: 909092
cord_uid: t807er8k

The COVID-19 pandemic has had a profound and often devastating impact on global healthcare systems. Healthcare systems have had to repurpose programs and staff as part of COVID-19 relief efforts. Antimicrobial stewardship programs (ASPs) have infrastructure and skilled personnel that have been utilized in new ways as part of COVID-19 pandemic response efforts. A critical focus of ASPs both before and during the pandemic is limiting the development of antimicrobial resistance. Fortunately, existing data indicate that rates of bacterial co-infection are relatively low and ASPs should continue aggressive efforts to limit unnecessary antimicrobial use. ASPs have taken a lead role in COVID-19 focused guideline creation and curation as well as in helping to steward access to potential novel therapeutic agents. Disparities in ASP program resources and personnel exist, and ASP activities focused on COVID-19 response should be tailored to individual settings. There is an urgent need for research to help inform ASP best practices within pandemic response efforts that takes into account local resources. Investment in infrastructure and personnel is urgently needed both in the context of current relief efforts and to prepare for future pandemics.

helping to steward access to potential novel therapeutic agents. Disparities in ASP program resources and personnel exist, and ASP activities focused on COVID-19 response should be tailored to individual settings. There is an urgent need for research to help inform ASP best practices within pandemic response efforts that takes into account local resources. Investment in infrastructure and personnel is urgently needed both in the context of current relief efforts and to prepare for future pandemics.

 Rates of bacterial co-infection with COVID-19 are relatively low but antibiotic use is high; judicious antibiotic use is critical to reduce the emergence of antibiotic resistance and to decrease toxicity from unnecessary antibiotics.

 Existing antimicrobial stewardship program infrastructure for guideline development, prospective audit and feedback along with antimicrobial restriction can be utilized directly in COVID-19 pandemic relief efforts.

 Antimicrobial stewardship programs can play important roles in stewarding access to novel or investigational therapeutic agents for SARS-CoV-2.

 Data on specific antimicrobial stewardship activities focused on COVID-19 relief are limited.

 There is an urgent need for research to help inform antimicrobial stewardship best practices within pandemic response efforts that take into account local resources.

 Investment in infrastructure and personnel is urgently needed both in the context of current relief efforts and to prepare for future pandemics.

As of May 20th, 2021 there have been 164,922,114 cases and 3,418,084 deaths from COVID-19 worldwide according to the COVID-19 Dashboard maintained by the Center for Systems Science and Engineering at Johns Hopkins University. Additionally, healthcare workers have comprised a significant number of cases ranging from 3.9%-13.1% and 0.5-1.9% of deaths in various studies. (Bandyopadhyay et al., 2020; Guerrero-Torres et al., 2020; Lapolla et al., 2021) The current pandemic is an unprecedented strain on the global healthcare system, which in addition to the loss of life has caused significant economic disruption leading to personal protective equipment (PPE) and medication shortages. (Badreldin and Atallah, 2021) The pandemic has also caused disruptions in routine access to care including routine procedures and mental healthcare. According to the United States Centers for Disease Control and Prevention an estimated 41% of U.S. adults delayed or avoided medical care relating to concerns about COVID-19. (Czeisler et al., 2020) 1.2 Antimicrobial overuse

The potential financial and human impacts of increasing antimicrobial resistance are well established. (O'Neill, 2016; World Health Organization, 2015) Prior to the COVID-19 pandemic, rates of antimicrobial resistance were increasing globally. (Oldenkamp et al., 2021) A major concern with the COVID-19 pandemic is that antimicrobial use in patients with COVID-19 will drive antimicrobial resistance.

Furthermore, there is concern that strained and overwhelmed healthcare systems will not be able maintain compliance with infection prevention and antimicrobial stewardship best practices, further driving the potential cross-transmission of antimicrobial resistant organisms.

There is some data to suggest antimicrobial prescribing in the outpatient setting has decreased during the pandemic according to data summarized from the IQVIA National Prescription Audit databases. (Buehrle et al., 2020) Initial decreases in prescribing patterns were attributed to a decrease in overall outpatient visits. However, sustained reductions in azithromycin, amoxicillin and levofloxacin were seen from April 2020 to July 2020 despite a rebound in ciprofloxacin, sulfamethoxazole-trimethoprim, clindamycin, doxycycline, nitrofurantoin, and cephalexin to pre-pandemic levels. (Buehrle et al., 2020) According to a recent meta-analysis including more than 30,000 patients, the prevalence of bacterial infection in COVID-19 is approximately 8.6%. (Langford et al., 2021) However, on average 64% of patients received antibiotics. (Langford et al., 2021) 115 out of the 154 examined studies were conducted in China. It was noted that as the pandemic continued the rate of prescribing decreased from a high of 82.8% of patients in January 2020 down to 62.6% in April 2020. The largest absolute prescribing rates were seen in Southeast and East Asia (excluding China) at 87.5% and the lowest rates in Europe at 63.1%. (Langford et al., 2021) In addition to the potential effect on antimicrobial resistance, significant increases in antimicrobial consumption in a pandemic setting can strain global supply and lead to medication shortages. Antimicrobial stewardship program (ASP) interventions are essential to prevent unnecessary antimicrobial prescribing.

1.3 Summary of available literature on Antimicrobial stewardship program's role during COVID-19

Existing ASP tools can be repurposed to serve a supporting role during a pandemic. Two of the most powerful tools in the ASP arsenal are prospective audit and feedback (PAF), and formulary restriction and preauthorization. These tools have been shown to have success in impacting the care of patients with COVID-19. (Kubin et al., 2021; Mazdeyasna et al., 2020; Tande et al., 2020) PAF can be applied to determine which patients may benefit most from diagnostic testing when resources are limited, or review appropriate use of COVID-19 focused medications and concomitant antimicrobial use. (Mazdeyasna et al., 2020) ASPs can also utilize PAF In order to assist with medication toxicity monitoring. An academic medical system in New York city reported generating ASP alerts for hydroxychloroquine without QTc monitoring and remdesivir without liver function studies. They also reported utilizing PAF to review frequency of antimicrobial administration to limit entering isolation rooms for medication administration. (Kubin et al., 2021) ASP interventions have been successfully expanded to guide use of novel or investigational therapeutics such as hydroxychloroquine, remdesivir and lopinavir/ritonavir to help ameliorate potential medication shortages. An observational study from the Mayo Clinic examined the effect of expanding ASP PAF activities to include hydroxychloroquine use review after seeing an 85% increase in utilization early in the pandemic. After PAF services were deployed they reported a reduction in hydroxychloroquine use to pre-pandemic levels. (Tande et al., 2020) ASPs can also work in coordination with microbiology to provide regular updates on institutional/local COVID-19 infection rates and to trend resistance in key organisms as well.

ASPs can also be involved in helping obtain access to novel therapeutics via other mechanisms such as assisting with completing paperwork for expanded access investigational drug applications and helping providers and patients navigate enrolling in clinical trials. (Michael P Stevens et al., 2020) Additionally, in the United States medications such as remdesivir and monoclonal antibodies available under emergency use authorization were provided by the federal government via local state health departments. Access to novel therapeutic agents under this mechanism can include local monitoring and reporting requirements. ASPs have taken leadership roles in helping providers and health systems navigate state specific access and reporting requirements.

Health system stresses related to the COVID-19 pandemic can also impact existing, non-COVID-19 focused, ASP activities. A case study from a six hospital New York City academic medical system comprising 2600 beds located within an early epicenter for COVID-19, reported a significant increase in alerts for post prescription review during the height of the pandemic. Additionally, these authors noted that time dedicated to traditional PAF activities was diverted to monitoring use of investigational agents and coordination with COVID-19 focused clinical trials. It was also noted that antimicrobial restriction was rescinded for levofloxacin in order to encourage less frequent dosing schedules, which allowed decreased healthcare worker exposure to isolation rooms. (Kubin et al., 2021) A separate report from a 1500-bed academic medical center noted a significant strain on the infectious diseases (ID) consult service relating to patients with known or suspected COVID-19. They describe a modification to their ASP workflow to identify patients with suspected or confirmed COVID-19 infection. These lists were reviewed daily by the ASP team to evaluate for therapeutic interventions, clinical trial enrollment, drug toxicity, antibiotic use and need for formal ID consultation. (Davis et al., 2020) During a pandemic, ASP resources and personnel may need to be expanded to prevent delays in approval and ensure pre-pandemic activities are not negatively impacted.

One of the authors on the current paper quantified the time impact of COVID-19 focused activities over a 13-month time span for his ASP: this included approximately 1,200 hours of work focused solely on COVID-19. The data in the literature are sparse but significant concern exists that a shift in focus to COVID-19 relief activities may have eroded traditional ASP efforts during the pandemic. It is also conceivable that some programs may have taken steps to bolster their ASPs during the pandemic. This may have included enhanced collaboration (or even integration) with infection prevention programs, expansion of existing personnel and the development of new data access and reporting infrastructure. Program enhancements that occurred during or as a result of the pandemic may enhance non-COVID-19 focused activities post-pandemic.

A survey conducted in May of 2020 in Ireland among 98 antimicrobial stewardship or Infectious Diseases personnel found that 76% of respondents reported a significant decrease in traditional ASP program effectiveness as a result of the pandemic. (Martin et al., 2021) Respondents had noted increased broad spectrum antimicrobial use, decreased adherence to local guidelines, resistance to de-escalation recommendations, decreased multi-drug-resistant organism (MDRO) monitoring, and drug shortages. (Martin et al., 2021) Conversely, a study from Singapore demonstrated that ASP acceptance rates were maintained during the pandemic, and patients with ASP interventions had decreased broad spectrum antimicrobial usage and length of stay. (Liew et al., 2020) There is significant disparity in regional rates of COVID-19 infection, resource availability and infrastructure. ASPs will need to develop policies and procedures that are suited for local institutions. Established infection prevention and control teams can also take on responsibilities of stewardship.

Disruption of global trade relating to the COVID-19 pandemic combined with increased medication utilization has led to widespread drug shortages. The importance of the ASP strategy of formulary restriction with pre-authorization has been highlighted during the pandemic: impacting both access to potential novel therapeutics and non-COVID-19 focused medications that may be in short supply. PAF and formulary restriction with pre-authorization are proven strategies to decrease antimicrobial consumption and can be applied to novel therapeutic agents for COVID-19 as previously mentioned. Additionally, some ASPs have been involved in stewarding non-antibiotic medications such as tocilizumab. ASPs have also been involved in helping to develop new mechanisms for key drug stock monitoring that often include non-antimicrobial medications including dexamethasone, tocilizumab, among others.

Comprehensive management of medication shortages is beyond the scope of this review. However, the WHO COVID-19 essential supplies ore asting tool ( COVID-ESFT) can be utilized to help predict shortages of medications, oxygen and PPE (available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Tools-Essential_forecasting-Overview-2020.1).

Local policies and guidelines should be developed for the distribution of novel or investigational therapeutic agents for COVID-19. Where resources allow, restriction and preauthorization measures should be instituted and be led by an ASP or pharmacy.

National and international guidance is available that can be adapted for local institutions. (National Institutes of Health, 2020; World Health Organization, 2021) Processes should be put in place that allow for frequent and rapid review of new literature and professional and government guidelines to allow for optimization of restriction and preauthorization measures in as close to real-time as possible.

Guidelines are available through the WHO, the Infectious Diseases Society of America (IDSA), United Kingdom National Institute for Health and Care Excellence (NICE) and the United States National Institutes of Health (NIH) that can be adapted for individual regions. These can be accessed from their respective websites free of charge.

The WHO recommends against the use of empiric antibiotics in patients with mild COVID-19.(World Health Organization, 2021) In patients with moderate disease antibiotics should be not be considered unless there is clinical concern for bacterial pneumonia with a recommendation to utilize WHO category Access antibiotics where appropriate. For patients with COVID-19 and shock the WHO recommends empiric antibiotics as a part of standard empiric bacterial sepsis coverage. (World Health Organization, 2021) The NICE guidelines state antibiotics should not be prescribed if COVID-19 is the likely cause of respiratory illness unless there is a suspicion for bacterial infection.(National Institute for Health and Care Excellence, 2021) According to the U.S. NIH, there is insufficient data to recommend empiric broad-spectrum antibiotics in patients with COVID-19 even with severe or critical illness without a clear indication.

They suggest if antimicrobials are initiated, they should be addressed daily for deescalation.(National Institutes of Health, 2020) Diagnostic tools are needed to identify patients with potential bacterial superinfection. Some patients with COVID-19 and superimposed bacterial infection have increased pro-calcitonin levels. (May et al., 2021) A retrospective study in the United Kingdom examining the impact of expanding National Health Service guidelines on limiting antibiotic use in patients with a procalcitonin of less than 0.25ng/mL found a more than 2-fold reduction in defined daily doses of antibiotic use without any increase in mortality among 368 patients. (Williams et al., 2021) A separate retrospective descriptive study discovered that procalcitonin values were elevated in patients with COVID-19 that were not believed to have bacterial pneumonia in 21% of cases. This population of patients with elevated procalcitonin and no evidence of bacterial pneumonia was found to have 1.8 additional days of antibiotics compared to patients with a negative procalcitonin (p<0.01). (Fabre et al., 2021) Alternative markers such as ferritin to procalcitonin ratio with a cutoff of ≥ 877 have reported a sensitivity of 85% and specificity of 56% for differentiating COVID-19 from bacterial pneumonia. However, patients with bacterial co-infection were excluded. (Gharamti et al., 2021) Other authors examined the baseline white blood cell count with the change in c-reactive protein with 48 hours of antibiotics and were able to exclude bacterial co-infection in 46% of cases among a cohort of 619 patients with COVID-19. They reported a sensitivity of this strategy at greater than 90% with a specificity of 43% for differentiating COVID-19 from bacterial pneumonia. (Mason et al., 2021) Overall, the data regarding the use of laboratory makers to risk stratify patients with COVID-19 who may have bacterial pneumonia are limited.

ASP programs can assist with appropriate utilization of antibiotics in patients with COVID-19 using previously mentioned strategies of guideline development, PAF, and antimicrobial restriction. Where resources allow, a process to review all antimicrobial prescribing in patients with COVID-19 can be considered. A recommended practice for antimicrobial prescribing in patients with COVID-19 can be seen in figure1. 

Close collaboration between antimicrobial stewardship and infection prevention and control teams is essential. Decreased antimicrobial use can directly impact personal-protective equipment usage and nursing exposures to COVID-19 by limiting patient encounters. (Jones et al., 2021) Many organizations (including the WHO and IDSA) have produced guidelines for infection prevention during the COVID-19 pandemic for both conventional and respiratory-PPE shortage settings.

The CDC provides guidance on criteria for diagnostic testing for patients with suspected COVID-19. A recent Cochrane review demonstrates that questionnaire or temperature based screening methods have poor sensitivity for detecting patients with COVID-19. (Viswanathan et al., 2020) Some inpatient institutions have implemented universal PCR testing for all admitted patients. (Sastry et al., 2020) Particularly in resource-limited settings ASPs can be involved in the diagnostic stewardship for SARS-CoV-2 through developing guidelines for testing and helping to identify patients who qualify for testing in coordination with infection prevention programs and microbiology laboratories. The WHO provides interim guidance on identifying patients for testing along with specimen collection and handling.(World Health Organization, 2020a) Data remains limited on ASP involvement in these activities. Anecdotal experience suggests these strategies can be employed in the inpatient setting, but evidence on their use is lacking.

When implementing telehealth, it will be important to consult local laws and regulations regarding its use along with addressing patient privacy concerns.

Global disparities in distribution of novel therapeutic agents exist and LMICs are most likely to be negatively impacted. It is critical that studies be done that ultimately will be relevant to all practice settings such as the WHO Solidarity trial.(WHO Solidarity Trial Consortium, 2021) It is also critical that trial results be analyzed in the most robust and practical way possible to make sure limited resources are being assigned to the potential therapeutics that are most likely to help patients.

Although outside the traditional scope of ASPs and there are limited data to support the practice, during the current pandemic ASPs have been involved in preauthorization and formulary restriction activities focused on non-antimicrobial agents such as tocilizumab. Additionally, a role for ASPs in the distribution of convalescent plasma has been proposed. (Michael P. Stevens et al., 2020) Similar principles have also been put forth to ration and appropriately allocate SARS-CoV2 vaccinations and monoclonal antibodies. Data on practical application of ASP initiatives in these domains are lacking currently.

There is emerging evidence of co-infections with invasive pulmonary aspergillosis associated with COVID-19 although the exact incidence is unknown with rates reported in the literature ranging from 3.8-34% with significant heterogeneity in diagnostic definitions. (Marr et al., 2021) The impact of COVID-19 on antifungal prescribing remains unknown. One study demonstrated no significant increase in antifungal prescribing after the onset of the pandemic (Nestler et al., 2021) and another demonstrated patients with COVID-19 were more likely to be prescribed antifungal therapy. (Seaton et al., 2020) Expert consensus from the European Confederation for Medical Mycology and the International Society for Human and Animal Mycology provides suggested criteria for testing, diagnosis and treatment of invasive aspergillosis associated with COVID-19. (Koehler et al., 2021) It should be noted there is also emerging evidence of increased rates of mucormycosis in patients with COVID-19, potentially related to corticosteroid use. This condition has significant associated mortality and could also drive antifungal prescriptions. (Singh et al., 2021) ASPs are essential in helping to determine appropriate use of antifungal therapy through interpretation of available literature and development of local guidelines along with potential restriction of antifungal agents where resources allow.

The impact of COVID-19 on antimicrobial resistance is unknown and will serve as a key target for future studies. Continued research on appropriate biomarkers to exclude bacterial co-infection in patients with COVID-19 are also needed. Additionally, the optimal role of ASPs in the restriction of non-antimicrobial medications such as tocilizumab and dexamethasone is unknown. Similarly, ASP's ideal role with the preauthorization and distribution of monoclonal antibodies as well as vaccines is unclear.

Further data will be needed to characterize how ASP resources can best be utilized in a pandemic setting. Such data could be utilized to rationalize formation or expansion of ASP as a part of pandemic preparedness. The ultimate impact of the COVID-19 pandemic on antimicrobial stewardship programs globally remains unknown.

The long-term impact of COVID-19 on antimicrobial stewardship, antimicrobial resistance and healthcare at large remain largely unknown. Available evidence suggests that rates of bacterial co-infection with COVID-19 are low but empiric antibiotic 21 use is high and ASPs will be critical in limiting unnecessary antimicrobial use.

Antimicrobial stewardship programs have taken on new roles during the pandemic including the creation and maintenance of COVID-19 focused treatment guidelines and the restriction of potential novel therapeutic agents including some non-antimicrobial agents. ASPs have also had to develop new mechanisms for real-time data review and dissemination. Disparities exist in access to both ASP personnel and program infrastructure that likely are only going to worsen given the stress on healthcare systems due to the COVID-19 pandemic. Additional research is needed to determine the most optimal ASP program resources and activities by setting as well as the ultimate impact of the pandemic on critical outcomes such as antimicrobial resistance.

Major opportunities exist to bolster programs to both help with ongoing pandemic response efforts and to prepare for future pandemics.

Ethical approval: Not required

Nationwide survey o pharma ists' involvement in antimicrobial stewardship programs in Nigerian tertiary hospitals

Global drug shortages due to COVID-19: Impact on patient care and mitigation strategies

Infection and mortality of healthcare workers worldwide from COVID-19: A systematic review

Use of Telemedicine and Virtual Care for Remote Treatment in Response to COVID-19 Pandemic

Impact of the coronavirus disease 2019 pandemic on outpatient antibiotic prescriptions in the United States

Using Telehealth to Expand Access to Essential Health Services during the COVID-19 Pandemic

Delay or Avoidance of Medical Care Because of COVID-19-Related Concerns -United States

Repurposing antimicrobial stewardship tools in the electronic medical record for the management of COVID-19 patients

The Role of Procalcitonin in Antibiotic Decision-Making in Covid-19 Infection

Diagnostic Utility of a Ferritin-to-Procalcitonin Ratio to Differentiate Patients With COVID-19 From Those With Bacterial Pneumonia: A Multicenter Study

Clinical Characteristics and Mortality of Health-Care Workers With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Mexico City

An international cross-sectional survey of antimicrobial stewardship programmes in hospitals

Antimicrobial stewardship interventions to minimize healthcare worker exposure to SARS-CoV-2

Defining and managing COVID-19

ECMM/ISHAM consensus criteria for research and clinical guidance

Antimicrobial stewardship perspectives from a New York City hospital during the COVID-19 pandemic: Challenges and opportunities

Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis

Deaths from COVID-19 in healthcare workers in Italy-What can we learn?

Antimicrobial stewardship programme: a vital resource for hospitals during the global outbreak of coronavirus disease 2019 (COVID-19)

Aspergillosis Complicating Severe Coronavirus Disease

Antimicrobial stewardship challenges and innovative initiatives in the acute hospital setting during the COVID-19 pandemic

Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics

Limited Utility of Procalcitonin in Identifying Community-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease

Antimicrobial Stewardship at the Core of COVID-19 Response Efforts: Implications for Sustaining and Building Programs

National Institute for Health and Care Excellence

Fungal superinfection in patients with COVID-19: Role of antifungal stewardship?

Rational allocation of COVID-19 vaccines to healthcare personnel and patients: A role for antimicrobial stewardship programs?

Tackling drug-resistant infections globally: Final report and recommendations

Filling the gaps in the global prevalence map of clinical antimicrobial resistance

Antimicrobial stewardship and bamlanivimab: Opportunities for outpatient preauthorization?

International Journal of Infectious Diseases Global Antimicrobial Stewardship with a Focus on Low-and Middle-Income Countries

Universal screening for the SARS-CoV-2 virus on hospital admission in an area with low COVID-19 prevalence

Survey of antibiotic and antifungal prescribing in patients with suspected and

Scottish hospitals

The CIDRAP Viewpoint

Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India

Involving antimicrobial stewardship programs in COVID-19 response efforts: All hands on deck

Antimicrobial Stewardship Programs and Convalescent Plasma for COVID-19: A New Paradigm for Pre-Authorization?

Leveraging Existing Strategies of

Medication Stewardship to Preserve and Appropriately Use Critical Supplies

The American Society of Health-System pharmacist

Universal screening for SARS-CoV-2 infection: a rapid review

WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Evaluation of procalcitonin as a contribution to antimicrobial stewardship in SARS-CoV-2 infection: a retrospective cohort study

World Health Organization. COVID-19 Clinical management Living guidance 2021

World Health Organization. Diagnostic testing for SARS-CoV

World Health Organization. Rational use of personal protective equipment for COVID-19 and considerations during severe shortages 2020b

World Health Organization. Global action plan on antimicrobial resistance